FDA Urged To Moderate Evidence Requirements In LDT Framework
This article was originally published in The Gray Sheet
Executive Summary
The agency will need to restrain evidence expectations for proving clinical validity in its planned framework for regulating laboratory-developed tests in order to make the framework more feasible, speakers at a Sept. 18 Avalere conference said.
You may also be interested in...
Experts Criticize FDA's Plan To Regulate Genomic Tests
Legal, ethics and genomic scholars took to the New England Journal of Medicine to criticize FDA's plan to regulate laboratory-developed tests.
FDA Releases LDT Regulatory Framework, Notification Draft Guidances
Two promised draft guidances on FDA’s framework for regulating laboratory developed tests and notification and medical device reporting requirements for LDTs have been posted. The agency wants swift notification from labs for most available LDTs once a framework is finalized.
Will Lab-Developed Test Makers Be Subject To Device Tax? It Depends, Shuren Suggests At Hearing
Lawmakers at a Sept. 9 House Energy and Commerce Subcommittee raised questions on whether FDA’s plans to regulate lab developed tests will also make labs subject to the device excise tax.